Novartis gets exclusive rights to Regenerex LLC's immunosuppressant technology; rights returned
Novartis AG has licensed exclusive worldwide rights to use Regenerex LLC’s Facilitating Cell Therapy (FCRx) stem cell platform.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.